AU2001261501A1 - Inhibition of the interaction of psd93 and psd95 with the nnos and nmda receptors - Google Patents

Inhibition of the interaction of psd93 and psd95 with the nnos and nmda receptors

Info

Publication number
AU2001261501A1
AU2001261501A1 AU2001261501A AU6150101A AU2001261501A1 AU 2001261501 A1 AU2001261501 A1 AU 2001261501A1 AU 2001261501 A AU2001261501 A AU 2001261501A AU 6150101 A AU6150101 A AU 6150101A AU 2001261501 A1 AU2001261501 A1 AU 2001261501A1
Authority
AU
Australia
Prior art keywords
psd93
psd95
nnos
inhibition
interaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001261501A
Inventor
Roger A. Johns
Yuanxiang Tao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
ROGER A JOHNS
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ROGER A JOHNS, Johns Hopkins University filed Critical ROGER A JOHNS
Publication of AU2001261501A1 publication Critical patent/AU2001261501A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2001261501A 2000-05-12 2001-05-14 Inhibition of the interaction of psd93 and psd95 with the nnos and nmda receptors Abandoned AU2001261501A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US20389400P 2000-05-12 2000-05-12
US60/203,894 2000-05-12
US24258000P 2000-10-23 2000-10-23
US60/242,580 2000-10-23
PCT/US2001/015372 WO2001087285A2 (en) 2000-05-12 2001-05-14 Inhibition of the interaction of psd93 and psd95 with the nnos and nmda receptors

Publications (1)

Publication Number Publication Date
AU2001261501A1 true AU2001261501A1 (en) 2001-11-26

Family

ID=26899012

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001261501A Abandoned AU2001261501A1 (en) 2000-05-12 2001-05-14 Inhibition of the interaction of psd93 and psd95 with the nnos and nmda receptors

Country Status (2)

Country Link
AU (1) AU2001261501A1 (en)
WO (1) WO2001087285A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005097090A2 (en) * 2004-04-05 2005-10-20 Icos Corporation AGENTS THAT DISRUPT PSD95 - nNOS INTERACTION, COMPOSITIONS CONTAINING THE SAME, AND THERAPEUTIC USES THEREOF
EE200600044A (en) * 2006-12-29 2008-12-15 Tartu Ülikool The antisense oligonucleotide and its use for down-regulation of peripheral neuronal 1-nitric oxide sase and pharmaceutical composition
EP3450446A1 (en) * 2016-04-27 2019-03-06 Biocells (Beijing) Biotech Co., Ltd. Treatment method for excitatory neurotoxicity-related injury
CN107312071B (en) * 2016-04-27 2018-11-06 拜西欧斯（北京）生物技术有限公司 The therapy of excititoxic associated injury
CN107913395B (en) * 2016-10-10 2019-12-13 拜西欧斯（北京）生物技术有限公司 Use of polypeptides associated with neuronal excitatory injury for preventing, alleviating or treating pain

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2208097A (en) * 1996-03-08 1997-09-22 Regents Of The University Of California, The Muscular dystrophy, stroke, and neurodegenerative disease diagnosis and treatment
GB9611584D0 (en) * 1996-06-04 1996-08-07 Univ Edinburgh Neurotransmitters
US6103872A (en) * 1998-01-22 2000-08-15 The Johns Hopkins University CAPON: a protein associated with neuronal nitric oxide synthase
CA2273622C (en) * 1999-06-02 2012-03-20 Michael Tymianski Inhibition of nmda receptor signalling in reducing neuronal damage

Also Published As

Publication number Publication date
WO2001087285A3 (en) 2002-08-15
WO2001087285A2 (en) 2001-11-22

Similar Documents

Publication Publication Date Title
AU2002235128A1 (en) Expression miniarrays and uses thereof
AU2002243246A1 (en) Cddo-compounds and combination therapies thereof
AU2001280599A1 (en) Compounds and methods
AU2001253418A1 (en) Compounds and methods
AU2002221749A1 (en) Synthetic viruses and uses thereof
AU2001240637A1 (en) Novel imidazotriazinones and the use thereof
AU2002223178A1 (en) Easy open end and can for powders
AU2002214404A1 (en) Products with biofunctional coating
AU2002211717A1 (en) Stresscopins and their uses
AU2001284493A1 (en) Deposit detector and controller using the detector
AU2001246934A1 (en) Agonist antibodies
AU2001243394A1 (en) Compounds and methods
AU2001249444A1 (en) Methods and compositions for the simultaneous detection of multiple analytes
AU2001292936A1 (en) Octahydro-indolizines and quinolizines and hexahydro-pyrrolizines
AU2002252015A1 (en) Pdz domain interactions and lipid rafts
AU2001225491A1 (en) Streak device
AU2001261750A1 (en) Laminate and its use
AU2001295185A1 (en) Multiplexing-interleaving and demultiplexing-deinterleaving
AUPQ872300A0 (en) Compounds and methods
AU2001261501A1 (en) Inhibition of the interaction of psd93 and psd95 with the nnos and nmda receptors
AU3724701A (en) Family 5 xyloglucanases
AU2002224137A1 (en) Coating device
AU2001278951A1 (en) Compounds and methods
AU2001276258A1 (en) Ceramic component and the use thereof
AU4432001A (en) Trityl-type compounds and their use